Epstein-Barr virus-induced epigenetic alterations following transient infection

International Journal of Cancer

Volumn 132, Issue 9, 2013, Pages 2076-2086

  Queen, Krista J ^a   Shi, Mingxia ^b   Zhang, Fangfang ^a,d   Cvek, Urska ^a,c   Scott, Rona S ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b Louisiana State University Health Sciences Center   (United States)

^c LOUISIANA STATE UNIVERSITY   (United States)

^d STONY BROOK UNIVERSITY   (United States)

Author keywords

chromatin; EMT; epigenetics; Epstein Barr virus

Indexed keywords

ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CELL MOTILITY; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; E CADHERIN GENE; EPIGENETICS; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; GENETIC ASSOCIATION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; LUNG CARCINOMA; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PYCARD GENE; VIRUS CARCINOGENESIS; VIRUS GENOME; VIRUS RECOMBINANT;

BLOTTING, WESTERN; CADHERINS; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; CPG ISLANDS; CYTOSKELETAL PROTEINS; DNA METHYLATION; EPIGENOMICS; EPSTEIN-BARR VIRUS INFECTIONS; GENE EXPRESSION PROFILING; HERPESVIRUS 4, HUMAN; HISTONES; HUMANS; LUNG NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84874047934     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27893     Document Type: Article

References (51)

1. Epstein MA, Achong BG, Barr YM,. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1964; 1: 702-3.
2. Herbst H, Stein H, Niedobitek G,. Epstein-Barr virus and CD30+ malignant lymphomas. Crit Rev Oncogenesis 1993; 4: 191-239.
3. Levine PH, Ablashi DV, Berard CW, et al. Elevated antibody titers to Epstein-Barr virus in Hodgkin's disease. Cancer 1971; 27: 416-21.
4. Pathmanathan R, Prasad U, Chandrika G, et al. Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx. Variants of Epstein-Barr virus-infected neoplasia. Am J Pathol 1995; 146: 1355-67.
5. Oda K, Tamaru J, Takenouchi T, et al. Association of Epstein-Barr virus with gastric carcinoma with lymphoid stroma. Am J Pathol 1993; 143: 1063-71.
6. Delecluse HJ, Marafioti T, Hummel M, et al. Disappearance of the Epstein-Barr virus in a relapse of Hodgkin's disease. J Pathol 1997; 182: 475-9.
7. Nerurkar AY, Vijayan P, Srinivas V, et al. Discrepancies in Epstein-Barr virus association at presentation and relapse of classical Hodgkin's disease: impact on pathogenesis. Ann Oncol 2000; 11: 475-8.
8. Xue SA, Labrecque LG, Lu QL, et al. Promiscuous expression of Epstein-Barr virus genes in Burkitt's lymphoma from the central African country Malawi. Int J Cancer 2002; 99: 635-43.
9. Thorley-Lawson DA, Duca KA, Shapiro M,. Epstein-Barr virus: a paradigm for persistent infection-for real and in virtual reality. Trends Immunol 2008; 29: 195-201.
10. Sample J, Brooks L, Sample C, et al. Restricted Epstein-Barr virus protein expression in Burkitt lymphoma is due to a different Epstein-Barr nuclear antigen 1 transcriptional initiation site. Proc Natl Acad Sci USA 1991; 88: 6343-7.
11. Bell AI, Groves K, Kelly GL, et al. Analysis of Epstein-Barr virus latent gene expression in endemic Burkitt's lymphoma and nasopharyngeal carcinoma tumour cells by using quantitative real-time PCR assays. J Gen Virol 2006; 87: 2885-90.
12. Tempera I, Lieberman PM,. Chromatin organization of gammaherpesvirus latent genomes. Biochim Biophys Acta 2010; 1799: 236-45.
13. Takacs M, Banati F, Koroknai A, et al. Epigenetic regulation of latent Epstein-Barr virus promoters. Biochim Biophys Acta 2010; 1799: 228-35.
14. Bryant H, Farrell PJ,. Signal transduction and transcription factor modification during reactivation of Epstein-Barr virus from latency. J Virol 2002; 76: 10290-8.
15. Gruffat H, Manet E, Sergeant A,. MEF2-mediated recruitment of class II HDAC at the EBV immediate early gene BZLF1 links latency and chromatin remodeling. EMBO Rep 2002; 3: 141-6.
16. Jenkins PJ, Binne UK, Farrell PJ,. Histone acetylation and reactivation of Epstein-Barr virus from latency. J Virol 2000; 74: 710-20.
17. Bhende PM, Seaman WT, Delecluse HJ, et al. The EBV lytic switch protein, Z, preferentially binds to and activates the methylated viral genome. Nat Genet 2004; 36: 1099-104.
18. Dickerson SJ, Xing Y, Robinson AR, et al. Methylation-dependent binding of the epstein-barr virus BZLF1 protein to viral promoters. PLoS Pathog 2009; 5: e1000356.
19. Heather J, Flower K, Isaac S, et al. The Epstein-Barr virus lytic cycle activator Zta interacts with methylated ZRE in the promoter of host target gene egr1. J Gen Virol 2009; 90: 1450-4.
20. Karlsson QH, Schelcher C, Verrall E, et al. Methylated DNA recognition during the reversal of epigenetic silencing is regulated by cysteine and serine residues in the Epstein-Barr virus lytic switch protein. PLoS Pathog 2008; 4: e1000005.
21. Niller HH, Wolf H, Minarovits J,. Epigenetic dysregulation of the host cell genome in Epstein-Barr virus-associated neoplasia. Semin Cancer Biol 2009; 19: 158-64.
22. Hino R, Uozaki H, Murakami N, et al. Activation of DNA methyltransferase 1 by EBV latent membrane protein 2A leads to promoter hypermethylation of PTEN gene in gastric carcinoma. Cancer Res 2009; 69: 2766-74.
23. Tsai CN, Tsai CL, Tse KP, et al. The Epstein-Barr virus oncogene product, latent membrane protein 1, induces the downregulation of E-cadherin gene expression via activation of DNA methyltransferases. Proc Natl Acad Sci USA 2002; 99: 10084-9.
24. Paschos K, Smith P, Anderton E, et al. Epstein-Barr virus latency in B cells leads to epigenetic repression and CpG methylation of the tumour suppressor gene Bim. PLoS Pathog 2009; 5: e1000492.
25. Skalska L, White RE, Franz M, et al. Epigenetic repression of p16(INK4A) by latent Epstein-Barr virus requires the interaction of EBNA3A and EBNA3C with CtBP. PLoS Pathog 2010; 6: e1000951.
26. Imai S, Nishikawa J, Takada K,. Cell-to-cell contact as an efficient mode of Epstein-Barr virus infection of diverse human epithelial cells. J Virol 1998; 72: 4371-8.
27. Matsuo Y, Nishizaki C, Drexler HG,. Efficient DNA fingerprinting method for the identification of cross-culture contamination of cell lines. Hum Cell 1999; 12: 149-54.
28. Repic AM, Shi M, Scott RS, et al. Augmented latent membrane protein 1 expression from Epstein-Barr virus episomes with minimal terminal repeats. J Virol 2010; 84: 2236-44.
29. Eberhardy SR, D'Cunha CA, Farnham PJ,. Direct examination of histone acetylation on Myc target genes using chromatin immunoprecipitation. J Biol Chem 2000; 275: 33798-805.
30. He X, Chang S, Zhang J, et al. MethyCancer: the database of human DNA methylation and cancer. Nucleic Acids Res 2008; 36: D836-41.
31. Ongenaert M, Van Neste L, De Meyer T, et al. PubMeth: a cancer methylation database combining text-mining and expert annotation. Nucleic Acids Res 2008; 36: D842-6.
32. Cavallaro U, Schaffhauser B, Christofori G,. Cadherins and the tumour progression: is it all in a switch? Cancer Lett 2002; 176: 123-8.
33. McConnell BB, Vertino PM,. TMS1/ASC: the cancer connection. Apoptosis 2004; 9: 5-18.
34. Graff JR, Herman JG, Myohanen S, et al. Mapping patterns of CpG island methylation in normal and neoplastic cells implicates both upstream and downstream regions in de novo methylation. J Biol Chem 1997; 272: 22322-9.
35. Stimson KM, Vertino PM,. Methylation-mediated silencing of TMS1/ASC is accompanied by histone hypoacetylation and CpG island-localized changes in chromatin architecture. J Biol Chem 2002; 277: 4951-8.
36. Tycko B,. Allele-specific DNA methylation: beyond imprinting. Hum Mol Genet 2010; 19: R210-20.
37. Kapoor-Vazirani P, Kagey JD, Powell DR, et al. Role of hMOF-dependent histone H4 lysine 16 acetylation in the maintenance of TMS1/ASC gene activity. Cancer Res 2008; 68: 6810-21.
38. White RE, Groves IJ, Turro E, et al. Extensive co-operation between the Epstein-Barr virus EBNA3 proteins in the manipulation of host gene expression and epigenetic chromatin modification. PLoS One 2010; 5: e13979.
39. Sharpless NE,. INK4a/ARF: a multifunctional tumor suppressor locus. Mutat Res 2005; 576: 22-38.
40. Wang L, Grossman SR, Kieff E,. Epstein-Barr virus nuclear protein 2 interacts with p300, CBP, and PCAF histone acetyltransferases in activation of the LMP1 promoter. Proc Natl Acad Sci USA 2000; 97: 430-5.
41. Wu DY, Krumm A, Schubach WH,. Promoter-specific targeting of human SWI-SNF complex by Epstein-Barr virus nuclear protein 2. J Virol 2000; 74: 8893-903.
42. Scholle F, Bendt KM, Raab-Traub N,. Epstein-Barr virus LMP2A transforms epithelial cells, inhibits cell differentiation, and activates Akt. J Virol 2000; 74: 10681-9.
43. Ellis AL, Wang Z, Yu X, et al. Either ZEB1 or ZEB2/SIP1 can play a central role in regulating the Epstein-Barr virus latent-lytic switch in a cell-type-specific manner. J Virol 2010; 84: 6139-52.
44. Yu X, Wang Z, Mertz JE,. ZEB1 regulates the latent-lytic switch in infection by Epstein-Barr virus. PLoS Pathog 2007; 3: e194.
45. Horikawa T, Yang J, Kondo S, et al. Twist and epithelial-mesenchymal transition are induced by the EBV oncoprotein latent membrane protein 1 and are associated with metastatic nasopharyngeal carcinoma. Cancer Res 2007; 67: 1970-8.
46. Pozharskaya V, Torres-Gonzalez E, Rojas M, et al. Twist: a regulator of epithelial-mesenchymal transition in lung fibrosis. PLoS One 2009; 4: e7559.
47. Horikawa T, Yoshizaki T, Kondo S, et al. Epstein-Barr Virus latent membrane protein 1 induces Snail and epithelial-mesenchymal transition in metastatic nasopharyngeal carcinoma. Br J Cancer 2011; 104: 1160-7.
48. Rountree MR, Bachman KE, Herman JG, et al. DNA methylation, chromatin inheritance, and cancer. Oncogene 2001; 20: 3156-65.
49. Shair KH, Schnegg CI, Raab-Traub N,. Epstein-Barr virus latent membrane protein-1 effects on junctional plakoglobin and induction of a cadherin switch. Cancer Res 2009; 69: 5734-42.
50. Fandy TE,. Development of DNA methyltransferase inhibitors for the treatment of neoplastic diseases. Curr Med Chem 2009; 16: 2075-85.
51. Stimson L, Wood V, Khan O, et al. HDAC inhibitor-based therapies and haematological malignancy. Ann Oncol 2009; 20: 1293-302.